Cargando…
Empowering drug off-target discovery with metabolic and structural analysis
Elucidating intracellular drug targets is a difficult problem. While machine learning analysis of omics data has been a promising approach, going from large-scale trends to specific targets remains a challenge. Here, we develop a hierarchic workflow to focus on specific targets based on analysis of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256842/ https://www.ncbi.nlm.nih.gov/pubmed/37296102 http://dx.doi.org/10.1038/s41467-023-38859-x |
_version_ | 1785057192447049728 |
---|---|
author | Chowdhury, Sourav Zielinski, Daniel C. Dalldorf, Christopher Rodrigues, Joao V. Palsson, Bernhard O. Shakhnovich, Eugene I. |
author_facet | Chowdhury, Sourav Zielinski, Daniel C. Dalldorf, Christopher Rodrigues, Joao V. Palsson, Bernhard O. Shakhnovich, Eugene I. |
author_sort | Chowdhury, Sourav |
collection | PubMed |
description | Elucidating intracellular drug targets is a difficult problem. While machine learning analysis of omics data has been a promising approach, going from large-scale trends to specific targets remains a challenge. Here, we develop a hierarchic workflow to focus on specific targets based on analysis of metabolomics data and growth rescue experiments. We deploy this framework to understand the intracellular molecular interactions of the multi-valent dihydrofolate reductase-targeting antibiotic compound CD15-3. We analyse global metabolomics data utilizing machine learning, metabolic modelling, and protein structural similarity to prioritize candidate drug targets. Overexpression and in vitro activity assays confirm one of the predicted candidates, HPPK (folK), as a CD15-3 off-target. This study demonstrates how established machine learning methods can be combined with mechanistic analyses to improve the resolution of drug target finding workflows for discovering off-targets of a metabolic inhibitor. |
format | Online Article Text |
id | pubmed-10256842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102568422023-06-11 Empowering drug off-target discovery with metabolic and structural analysis Chowdhury, Sourav Zielinski, Daniel C. Dalldorf, Christopher Rodrigues, Joao V. Palsson, Bernhard O. Shakhnovich, Eugene I. Nat Commun Article Elucidating intracellular drug targets is a difficult problem. While machine learning analysis of omics data has been a promising approach, going from large-scale trends to specific targets remains a challenge. Here, we develop a hierarchic workflow to focus on specific targets based on analysis of metabolomics data and growth rescue experiments. We deploy this framework to understand the intracellular molecular interactions of the multi-valent dihydrofolate reductase-targeting antibiotic compound CD15-3. We analyse global metabolomics data utilizing machine learning, metabolic modelling, and protein structural similarity to prioritize candidate drug targets. Overexpression and in vitro activity assays confirm one of the predicted candidates, HPPK (folK), as a CD15-3 off-target. This study demonstrates how established machine learning methods can be combined with mechanistic analyses to improve the resolution of drug target finding workflows for discovering off-targets of a metabolic inhibitor. Nature Publishing Group UK 2023-06-09 /pmc/articles/PMC10256842/ /pubmed/37296102 http://dx.doi.org/10.1038/s41467-023-38859-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Chowdhury, Sourav Zielinski, Daniel C. Dalldorf, Christopher Rodrigues, Joao V. Palsson, Bernhard O. Shakhnovich, Eugene I. Empowering drug off-target discovery with metabolic and structural analysis |
title | Empowering drug off-target discovery with metabolic and structural analysis |
title_full | Empowering drug off-target discovery with metabolic and structural analysis |
title_fullStr | Empowering drug off-target discovery with metabolic and structural analysis |
title_full_unstemmed | Empowering drug off-target discovery with metabolic and structural analysis |
title_short | Empowering drug off-target discovery with metabolic and structural analysis |
title_sort | empowering drug off-target discovery with metabolic and structural analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256842/ https://www.ncbi.nlm.nih.gov/pubmed/37296102 http://dx.doi.org/10.1038/s41467-023-38859-x |
work_keys_str_mv | AT chowdhurysourav empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis AT zielinskidanielc empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis AT dalldorfchristopher empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis AT rodriguesjoaov empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis AT palssonbernhardo empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis AT shakhnovicheugenei empoweringdrugofftargetdiscoverywithmetabolicandstructuralanalysis |